 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
LigoCyte has developed the capability for
construction and application of live vector (plasmid
containing) vaccines or novel carrier systems
(stable polymerized liposomes) that are engineered
to express or display peptide mimics of molecules
associated with the virulence of pathogenic
organisms. These vaccines are designed to elicit
potent immune responses, including those that operate at mucosal
surfaces where most infectious agents enter the body. Mucosal
vaccine technology has broad applications including the prevention
or treatment of most bacterial, viral, fungal and parasitic diseases
and many forms of cancer in humans as well as animals.
Products in Development at LigoCyte A number of antigen constructs are being developed in-house at LigoCyte for vaccine applications. These include: Group B Streptococcus E. coli 0157:H7 Candida albicans Brucella Norwalk Partnering Opportunities LigoCyte Pharmaceuticals will partner the M cell targeting technology with companies that have identified proprietary antigens for diseases or infections associated with mucosal tissues (respiratory, uro-genital, intestinal, etc.). LigoCyte will also pursue projects with corporate partners in nasal and oral delivery of vaccine constructs. This robust antigen DNA delivery technology enables the development of vaccine constructs which can be delivered via mucosal tissues (e.g., oral, nasal, etc.). Mucosal IgA, serum IgG and cell-mediated immune responses are generated following vaccination.
For additional information regarding LigoCyte's M
cell targeting technology, please contact: |
LigoCyte's DNA Vaccine Technology is a broad-based patent-pending technology for Peptide-DNA
vaccine development.
LigoCyte's M cell targeting technology is built upon
the foundation of the company's cell trafficking
expertise. Using a viral adhesin protein, LigoCyte scientists
have developed a vaccine construct which very
efficiently targets mucosal inductive tissues via interaction
with M cells. Because M cells facilitate antigen uptake,
this technology promotes efficient antigen processing
by antigen presenting cells located proximal to M cells
in mucosal inductive tissues such as the Peyer's patch.
Targeting adhesin molecule binds NALT (nasal associated
lymphoid tissue) M cells. A frozen section of normal murine BALB/c NALT
was reacted with recombinant targeting adhesin (red) and UEA-1 (green).
a) Phase contrast image at 190x; (b) targeting adhesin (yellow arrows)
and UEA-1 (white arrows) binding to NALT M cells, and under high
magnification (~380x) reveals targeting adhesin (red) binding to the apical
surface of an M cell (bright green) as well as localizing within the M cell
itself (yellow).
Expression of DNA delivered by
targeting construct.